Drugs / ST-503
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06980948 | Dec 2025 → Jul 2027 expected | neuropathy, painful | Sangamo Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ST-503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06980948 ↗ |
| Action | Inhibit | “ideally repress Nav1.7 tissue-related pain signals” NCT06980948 ↗ |
| Route | Intrathecal | “Single Dose Intrathecal ST-503 Gene Therapy” NCT06980948 ↗ |